Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Grant of Options

19 Dec 2012 15:14

RNS Number : 9500T
Allergy Therapeutics PLC
19 December 2012
 



19 December 2012

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

 

Grant of Options

 

Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP'), on 19 December 2012 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors, Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:

 

Director

Number of provisional shares awarded

Date of distribution

Total provisional shares held under LTIPs

Manuel Llobet

720,000

19 December 2012

2,160,000

Ian Postlethwaite

360,000

19 December 2012

1,080,000

 

 

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of the three years ending 30 June 2015.

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBUBDDDBBBGDC
Date   Source Headline
5th Feb 20073:04 pmRNSHolding(s) in Company
31st Jan 200710:18 amRNSTotal Voting Rights
31st Jan 20077:01 amRNSResearch Update
26th Jan 200710:00 amRNSOpening of Facilities
23rd Jan 20077:01 amRNSResearch Update
15th Jan 20077:00 amRNSNotice of Results
12th Dec 200611:59 amRNSHolding(s) in Company
11th Dec 20063:45 pmRNSHolding(s) in Company
7th Dec 20063:12 pmRNSDirector/PDMR Shareholding
7th Dec 20067:02 amRNSResearch Update
5th Dec 20062:30 pmRNSTotal Voting Rights
6th Nov 200612:12 pmRNSDirector/PDMR Shareholding
3rd Nov 20069:20 amRNSResult of AGM
2nd Nov 200611:39 amRNSDirector/PDMR Shareholding
27th Oct 200610:58 amRNSDirector/PDMR Shareholding
11th Oct 20067:00 amRNSClinical Trials
12th Sep 20067:04 amRNSFinal Results
19th Jul 20067:01 amRNSClinical update
14th Jul 20067:01 amRNSTrading Statement
7th Jul 20064:17 pmRNSDirector/PDMR Shareholding
4th Jul 20067:00 amRNSClinical update
3rd Jul 20064:08 pmRNSHolding(s) in Company
21st Jun 20067:00 amRNSClinical update
11th May 20067:02 amRNSApproval of Vaccine patent
10th May 20063:43 pmRNSDirector/PDMR Shareholding
8th May 200611:44 amRNSHolding(s) in Company
4th May 200612:06 pmRNSEGM Statement
10th Apr 20067:02 amRNSIssue of Equity
28th Mar 20064:28 pmRNSHolding(s) in Company
27th Mar 20067:01 amRNSInterim Results
24th Mar 20067:02 amRNSClinical update
16th Mar 20069:29 amRNSNotice of Results-Amendment
6th Mar 20067:03 amRNSClinical update
1st Mar 20069:30 amRNSNotice of Results
27th Feb 20061:02 pmRNSHolding(s) in Company
9th Jan 20063:32 pmRNSHolding(s) in Company
15th Dec 20057:01 amRNSDirector/PDMR Shareholding
6th Dec 20054:17 pmRNSHolding(s) in Company
2nd Dec 20057:01 amRNSClinical update
22nd Nov 20057:03 amRNSDirectorate change and update
17th Nov 20051:08 pmRNSHolding(s) in Company
14th Nov 20057:01 amRNSChange of Adviser
7th Nov 20057:00 amRNSDirectorate Change
4th Nov 20053:05 pmRNSResult of AGM
25th Oct 20052:27 pmRNSDirector/PDMR Shareholding
13th Sep 20057:01 amRNSFinal Results
24th Aug 20057:00 amRNSChange of Adviser
18th Jul 20057:01 amRNSTrading Statement
11th May 20057:00 amRNSHolding(s) in Company
10th May 20057:01 amRNSClearance for vaccine studies

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.